Pharmacyclics gets $50M milestone payment from J&J MarketWatch The trial involves Pharmacyclics's drug ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Pharmacyclics last received a milestone payment in ... |
